Feature

A Simpler, Smarter CHO Strategy for High-Quality Bispecifics

Here’s how next-generation cell line and manufacturing methods can boost productivity, improve purity, and remove bottlenecks in bispecific antibody development

Share

In a recent webinar, practical strategies to enhance bispecific antibody production using CHO cell lines were discussed, with a focus on an antibiotic-free platform leveraging the glutamine synthetase selection marker. This innovative approach aims to simplify the development process of these complex therapeutics, ensuring high yields and purity while utilizing advanced molecular design and continuous manufacturing techniques. Just-Evotec Biologics aims to revolutionize biotherapeutics access through optimized bioprocessing workflows.

Original Source(s)

A Simpler, Smarter CHO Strategy for High-Quality Bispecifics

Here’s how next-generation cell line and manufacturing methods can boost productivity, improve purity, and remove bottlenecks in bispecific antibody development

  • by Yiting Lim

  • February 19, 2026

  • 10 min

Related Content

UK Increase in Advanced Therapy Clinical Trials

Number of early-stage trials remains high, according to CGT Catapult data

  • January 26, 2026

  • 2 min
Targeting the Untouchables: Covalent Peptides That Target Elusive Transcription Factors

Researchers have developed a new way to create covalent peptide inhibitors of transcription factors – proteins once considered “undruggable.”

  • June 27, 2025

  • 9 min
Rethinking the Role of Lymph Nodes in Prostate Cancer: A study from Mount Sinai

In this study, Ash Tewari, MD and additional authors at Mount Sinai suggest re-evaluating the common practice of removing lymph nodes during prostate cancer surgery, as it can be risky and may not provide therapeutic benefits.

  • by

  • August 2, 2024

  • 1 min